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Abstract
Objective
To evaluate the clinical and cost-effectiveness of non-medical prescribing (NMP).
Design
Systematic review. Two reviewers independently completed searches, eligibility assess-
ment and assessment of risk of bias.
Data sources
Pre-defined search terms/combinations were utilised to search electronic databases. In
addition, hand searches of reference lists, key journals and grey literature were employed
alongside consultation with authors/experts.
Eligibility criteria for included studies
Randomised controlled trials (RCTs) evaluating clinical or cost-effectiveness of NMP. Mea-
surements reported on one or more outcome(s) of: pain, function, disability, health, social
impact, patient-safety, costs-analysis, quality adjusted life years (QALYs), patient satisfac-
tion, clinician perception of clinical and functional outcomes.
Results
Three RCTs from two countries were included (n = 932 participants) across primary and ter-
tiary care settings. One RCT was assessed as low risk of bias, one as high risk of bias and
one as unclear risk of bias. All RCTs evaluated clinical effectiveness with one also evaluat-
ing cost-effectiveness. Clinical effectiveness was evaluated using a range of safety and
patient-reported outcome measures. Participants demonstrated significant improvement in
outcomes when receiving NMP compared to treatment as usual (TAU) in all RCTs. An
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associated cost analysis showed NMP to be more expensive than TAU (regression coeffi-
cient p = 0.0000), however experimental groups generated increased QALYs compared to
TAU.
Conclusion
Limited evidence with overall unclear risk of bias exists evaluating clinical and cost-effective-
ness of NMP across all professions and clinical settings. GRADE assessment revealed
moderate quality evidence. Evidence suggests that NMP is safe and can provide beneficial
clinical outcomes. Benefits to the health economy remain unclear, with the cost-effective-
ness of NMP assessed by a single pilot RCT of low risk of bias. Adequately powered low risk
of bias RCTs evaluating clinical and cost effectiveness are required to evaluate NMP across
clinical specialities, professions and settings.
Registration
PROSPERO (CRD42015017212).
Introduction: Rationale
Non-medical prescribing (NMP) contributes to the effective management of both acute and
chronic conditions which require prescription of appropriate medication in a timely manner,
without the service users’ needs being affected by health services’ staffing deficiencies, financial
concerns or geographical location [1]. It is utilised by a range of professions, with limited con-
sistency regarding definition and terminology internationally [2]. In recent years, the UK gov-
ernment has expanded the scope of NMP that now includes nursing, pharmacy, podiatry,
radiography, optometry, physiotherapy and dietetic professions, with the potential to expand
further to include paramedicine [3].
With the ever-increasing financial challenges faced by health services, in part due to ageing
populations and rising levels of chronic disease, the potential financial efficiencies gained
through the use of NMP are of paramount importance [3, 4]. A range of robust studies utilis-
ing survey designs have concluded that NMP practice is both safe and appropriate, exhibiting
good patient satisfaction [5–9]. Despite this, the implementation of NMP in the UK remains at
a relatively slow pace [3]. Although the reasons for this are unclear, it is argued that this is
caused by a lack of persuasive high quality evidence demonstrating the clinical and economic
benefits of NMP in comparison to current models of healthcare [3]. As demand for healthcare
increases, it is likely that policy makers and healthcare departments will become increasingly
interested in optimising the skills of all health professionals to streamline patient care [3].
Employing non-medical prescribers within healthcare services has the potential to make sav-
ings across a range of health specialties, providing more holistic patient care within an individ-
ual profession’s scope of practice [3, 4, 10].
For NMP to become more widely accepted, healthcare managers, clinical care quality and
safety agencies, as well as the general public require evidence of the overall value of NMP;
through the implementation of services that are patient-centred, improving the quality and
safety of patient care, while simultaneously reducing costs and improving efficiency of treat-
ment and patient-outcomes [3, 11]. A robust evaluation of NMP is imperative to ensure qual-
ity, and appropriate and efficient use of medicines [12]. The advantages, although anecdotal,
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are evident in results from case studies and clinical audits which demonstrate that NMP has a
good safety record and benefits both patients and clinical services [3, 5]. A recent Cochrane
review compared resource utilisation and assessed for non-inferiority in clinical outcome mea-
sures and patient reported outcomes of NMP to medical prescribing, concluding that non-
medical prescribers provide comparable care across a range of clinical specialties [13]. This
systematic review included high risk of bias evidence from controlled trials (Randomised con-
trolled trials (RCTs), cluster-RCTs, controlled before-and-after (CBA) studies and interrupted
time series analysis). The future development of NMP across professions internationally is
dependent on low risk of bias evidence regarding clinical and cost-effectiveness; without
which, it is difficult to demonstrate that NMP offers quality care and patient safety [3]. To
date, no systematic review has synthesised this existing evidence.
Objective
To evaluate the clinical and cost effectiveness of NMP.
Methods
A systematic review was conducted according to a pre-defined protocol informed by the
Cochrane handbook [14–17], and is reported in accordance with the PRISMA statement [17,
18]. The systematic review protocol was registered with PROSPERO (CRD42015017212) to
ensure transparency [15, 19]. This article reports objective 1 of the published protocol.
Eligibility criteria
Inclusion criteria
Studies. Randomised controlled trials (RCTs) or pilot RCTs that evaluated the clinical or
cost effectiveness of NMP.
Participants. Health service users receiving treatment from non-medical prescribers
from any professional group with appropriate authority to prescribe medicines via supplemen-
tary or independent prescribing mechanisms [20].
Intervention. Non-medical prescribing provided by a professional group with appropri-
ate authority to prescribe medicines via supplementary or independent prescribing mecha-
nisms [20]
Comparators. Inter- or intra-profession comparisons of clinical and cost effectiveness,
pre and post intervention comparisons of clinical outcomes [14, 21].
Outcome Measures. Measurements reported on one or more outcome of: pain, func-
tional impairment, disability, health, social impact, patient safety, associated costs analysis,
quality adjusted life years (QALYs), patient satisfaction, clinician perception of clinical and
functional outcomes [14].
Exclusion criteria. studies not written in English [18].
Information sources
The literature search employed sensitive topic-based strategies designed for each of the sources
identified in Fig 1.
Search
Pre-defined search terms and combinations, with database specific standardised vocabulary
were employed to ensure all relevant studies were retrieved [14, 21–23]. Fig 2 illustrates an
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example full electronic search strategy for studies investigating clinical effectiveness in Medline
OvidSP. Where a pilot study was identified, the definitive study was sought, or the authors
contacted to determine whether further published or unpublished research had been under-
taken. The reference lists of the identified literature were searched to ensure no studies were
missed [21, 23]. In addition, experts in the area were consulted to detect any further studies
[14, 21–23].
Study selection
Two investigators searched information sources (TN/EGC) and independently assessed stud-
ies for inclusion by grading each eligibility criterion. In the event of a selection disagreement a
third reviewer (AR, methodological expert) was available to mediate any conflict [19, 22]. Both
reviewers independently evaluated studies by title and abstract for potential eligibility. Follow-
ing discussion between reviewers, if a study could not explicitly be excluded on the basis of its
title and abstract, its full text was reviewed [15, 17]. All potentially relevant studies proceeded
forward to the review of full text. The two independent reviewers made independent judge-
ments as to whether or not an individual study was included in the review based on the study’s
full text fulfilling the eligibility criteria. The numbers of studies included and excluded at the
different stages were recorded [14, 19, 21].
Data collection process
Data extraction was performed by the primary reviewer (TN) and checked and agreed by the
secondary reviewer (EGC). Data extraction utilised pre-determined data extraction sheets spe-
cific to the review objective which had been piloted, refined and agreed by the researchers
prior to use, ensuring that all relevant data were extracted [19, 21]. Any differences were
resolved at a consensus meeting of all authors [22], and the third reviewer (AR) checked for
consistency and clarity.
Databases Search:
CINAHL, EMBASE, MEDLINE, AMED, NHS Economic Evaluation database, NICE, Medicines 
Complete
Cochrane Central Register of Controlled Trials
Selected internet sites:
PUBMED, Turning Research into Practice, Current Controlled Trials website (York), Google 
Scholar, the Royal college of Nursing, Royal Pharmaceutical Society, King’s Fund, National 
Institute of Clinical Excellence, Department of Health, National prescribing Centre, Char-
tered Society of Physiotherapy, Society of Chiropodists and Podiatrists, American Associa-
tion of Nurse Practitioners, Australian College of Nurse Practitioners, Canadian Pharmacists 
Association, Optometry Australia, British Optometry Association.
National Research Register
Expert Opinion
Hand searches- key journals
Fig 1. Information sources utilised.
https://doi.org/10.1371/journal.pone.0193286.g001
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Data items
Study design, profession of prescribers, type of non-medical prescribing, participants (patient
groups) and indications, interventions, study settings, timing of assessments, and outcome
measures were extracted [14], to allow for assessment of homogeneity [14, 21].
Risk of bias
Each reviewer independently assessed the internal validity of each included trial using the
Cochrane Risk of Bias Tool [14, 24]. This tool was selected as it was developed to specifically
assess bias within RCTs [14, 24]. The tool has been evaluated and has been shown to exhibit
good inter-rater reliability [25]. Results were tabulated to demonstrate of the risk of bias across
included trials [24].
Summary measures and synthesis of results
An explanation of each included trial’s characteristics and outcome data were tabulated.
Within and between studies analyses was undertaken in the context of risk of bias [15, 18].
1. independent* prescrib*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device 
manufacturer, drug manufacturer, device trade name, keyword]
2. supplementary prescrib*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device 
manufacturer, drug manufacturer, device trade name, keyword]
3. nurs* prescrib*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device manufacturer, 
drug manufacturer, device trade name, keyword]
4. pharmac* prescrib*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device manufac-
turer, drug manufacturer, device trade name, keyword]
5. podiatr* prescrib*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device manufactur-
er, drug manufacturer, device trade name, keyword]
6. chiropad* prescrib*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device manufac-
turer, drug manufacturer, device trade name, keyword]
7. radiograph* prescrib*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device manu-
facturer, drug manufacturer, device trade name, keyword]
8. optometr* prescrib*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device manufac-
turer, drug manufacturer, device trade name, keyword]
9. physiotherap* prescrib*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device 
manufacturer, drug manufacturer, device trade name, keyword]
10. physio* prescrib*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device manufac-
turer, drug manufacturer, device trade name, keyword]
11. autonomous prescrib*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device 
manufacturer, drug manufacturer, device trade name, keyword]
12. non-medical prescrib*.mp.
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. Clinical eﬀecve*.mp.
15. Treatment outcome*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device manu-
facturer, drug manufacturer, device trade name, keyword]
16. Error*.mp. [mp=tle, abstract, heading word, drug trade name, original tle, device manufacturer, drug 
manufacturer, device trade name, keyword]
17. clinical eﬀecveness/
18. medicaon error/
19. 14 or 15 or 16 or 17 or 18
20. 13 and 19 
Fig 2. Full electronic search strategy for Medline OvidSP (clinical effectiveness). Originally undertaken: 25th May 2015. Most recently
undertaken: 1st November 2016.
https://doi.org/10.1371/journal.pone.0193286.g002
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Results
Study selection
The search strategy identified 373 potentially relevant studies. Following screening for dupli-
cates, 61 citations remained. No relevant unpublished studies were found and no further stud-
ies were identified from the Internet searches, reviews of the national research register or via
experts in the field. Reviewing by title and abstract excluded 158 studies that were not RCTs.
The full texts of the remaining 3 trials [26–28] were examined in detail and evaluated as meet-
ing the inclusion criteria. A further article [29] retrieved when examining the reference lists of
retrieved studies was included as it presented additional data to an included RCT. The data
from the two articles were considered as one pilot trial (The PIPPC pilot trial) [26, 29]. There-
fore, 3 trials (2 definitive trials and 1 pilot trial) were included (Fig 3). All included trials inves-
tigated clinical effectiveness (n = 3) [27–29]; 1 trial investigated cost effectiveness [26]. Fig 3
presents the number of studies at each stage of the selection process. 100% inter-reviewer
agreement was achieved following open discussion at each stage. Third reviewer mediation
was not required.
Study characteristics
Study characteristics and descriptive data for the 3 included trials are summarised in Table 1.
All 3 trials involved pharmacy as the NMP profession evaluated in the experimental arms of
trials. The setting for one trial was the UK [26, 29], and for two was Australia [27, 28]. All
included trials compared pharmacist prescribing within a service or specific patient population
to usual care.
A total of 932 participants with an age range of 18–89 years, were randomised across the 3 tri-
als. Details regarding the participants’ specific diagnoses were not disclosed. Participants were
either: admitted to a tertiary hospital for surgery, involving an overnight stay [27, 28], or received
regular prescriptions for medication for chronic pain within a primary care setting [26, 29].
Two trials were completed at single site surgical departments of tertiary hospitals in Austra-
lia (Brisbane, Queensland and Newcastle, New South Wales)[27, 28], with a third trial under-
taken in primary care across six general practices in the UK (England and Scotland). The type
and scope of non-medical prescribing utilised by the pharmacists varied. One trial guided by
protocols, used supplementary prescribing to prescribe the patients’ regular medication [28].
One trial used independent prescribing only, where the scope of prescribing was to either con-
tinue or withhold regular medications and to prescribe VTE prophylaxis in accordance with
local and Australian guidelines [27], and a single trial, owing to regulations in place at the time
of study, utilised supplementary prescribing to prescribe controlled drugs and independent
prescribing for all other required medications [26, 29].
The prescribing pharmacists in two trials were registered independent pharmacist prescrib-
ers having completed an Independent Pharmacist Prescribing Course accredited by the Gen-
eral Pharmaceutical Council, UK [26, 27, 29]. An amendment to the Queensland Health
(Drugs and Poisons) Regulation 1996 enabled the qualified pharmacists to prescribe in
Queensland, Australia [27]. There was no disclosure of the mechanisms (qualification/
credentialing/accreditation) that were required for the pharmacists to undertake legal supple-
mentary prescribing in the trial completed in New South Wales, Australia [28].
Outcomes: Clinical effectiveness
Primary outcome measures assessing clinical effectiveness varied. Bruhn et al (2013) used the
SF12v2 and the Health Utilities Index (HUI). However, because licencing costs were required
Clinical and cost-effectiveness of non-medical prescribing: A systematic review of RCTs
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to score the data, the HUI was not subsequently analysed. Hale et al (2013) and Marotti et al
(2011) did not specify a validated patient reported outcome measure, however they analysed
the safety of NMP practice, assessing the frequency of omission and prescribing errors when
compared against a patient’s medical history, and the number of medication doses inappropri-
ately missed during an inpatient stay respectively.
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Fig 3. Study selection flow diagram (adapted from Moher et al, 2009)[18].
https://doi.org/10.1371/journal.pone.0193286.g003
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Table 1. Study characteristics of included trials.
Trial Design Participants & Indication Intervention & Setting Outcome Measures Between Group Results Additional Information
The PIPPC
Trial
(Neilson
et al, 2015,
Bruhn,
2013)[26,
29]
Pilot RCT:
Three Groups:
A. Pharmacist medication
review plus face-to-face
prescribing
B. Pharmacist medication
review with GP
prescribing
C. Treatment as usual
Recruitment March-June
2010
• Patients >18 years, living
independently, receiving
regular prescribed
medication for pain.
• Patients must have
received 2 acute
prescriptions within the
preceding 120 days for an
analgesic and/or NSAID.
• GPs excluded patients
with severe mental illness,
recent bereavement,
alcohol/drug addiction
and cancer pain
Baseline:
A. n = 68
B. mean (SD) age 66.1
(12.1),
C. 54.4% female
n = 62, age 65.7 (14.2),
46% female
n = 63, age 64.9 (11.6),
37% female
A: Face-to-face pharmacist
prescribing, with pre-
consultation paper-based
medication review; patients
completed a pain diary. All
non-controlled drugs issued
via IP. Controlled drugs
issued by SP (regulations at
the time).
B: Pharmacists undertook
paper-based medication
reviews focussed on pain
related prescription
medications,
implementation by GPs.
C: Treatment as usual GP
care
X6 pharmacist prescribers
utilised
Setting:
• GP practices, primary care
pharmacies.
• UK (Scotland & England)
Primary Clinical outcome:
SF12v2
Health Utilities Index (data
not analysed due to
licencing laws)
Secondary Clinical:
CPG
HADS
Primary Economic:
Costs associated with:
• Intervention (source-
PSSRU 2009/2010)
• pain related
hospitalisation (source- IDS
Scotland March 2010)
• primary care visits for
chronic pain (source-
PSSRU 2009/2010)
• primary care telephone
contacts for chronic pain
(source- PSSRU 2009/2010)
• OTC pain related
medication: Source- BNF
61, March 2011
Secondary- Effect of
pharmacist-led intervention:
QALYs- based on SF-6D
Clinical outcomes:
SF12v2: no statistical
significant difference
between groups.
CPG: Statistically
significant improvement
for group A compared to
groups B&C for intensity
(p = 0.02) but not disability
(p = 0.55).
HADS: Statistically
significant improvement in
HADS scores for group A
compared to group B&C
(A: p = 0.022; D: p = 0.045)
Cost effectiveness outcomes:
Resource use and costs:
Positive incremental mean
cost differences reported
for groups A&B compared
to C, indicating group A&B
interventions are more
expensive than group C.
QALYs: After adjusting for
baseline SF-6D scores,
baseline costs/controlling
for baseline patient
characteristics, QALYs for
groups A&B were largely
unchanged relative to
group C.
NMP Qualification:
Independent Pharmacist
Prescribing Course
accredited by the General
Pharmaceutical Council,
UK.
NMP- Pharmacists
Independent Prescribing,
supplementary
prescribing.
Exploratory trial to
estimate the sample size
for full trial- no formal
power calculation.
Optimal trial size
estimated at 780 per
group for full study.
Hale et al,
2013[27]
RCT:
Two Groups:
A. Pharmacist generated
medication chart/plan for
peri-operative
medication/ prescribed
VTE prophylaxis.
B. TAU.
Post consent, patients
randomised using
computer-generated
randomisation in blocks
of 10. Independently
prepared sealed envelopes
containing 1 or 0 then
determine allocation.
Conducted between June-
Sept 2009.
All patients > 18 years,
who attended the PAC.
Patients were excluded if
unable to communicate
due to language barrier or
undergoing day surgery.
Baseline:
A. n = 190, mean (mean
range) age 57.6 (18–89),
58% male
B. n = 194, mean (mean
range) age 55.8 (18–86),
59% male
Intervention:
Group A: Patients seen by a
nurse, prescribing
pharmacist, RMO and
anaesthetist. (Pharmacist
prior to RMO). Pharmacist
undertook duties as per
usual care, plus prescribing.
The scope of prescribing:
continuing/ withholding
regular medications &
prescribing VTE
prophylaxis according to
local & national guidelines.
Group B: all 4 professionals
consulted in no particular
order. Prescribing was the
responsibility of the RMO.
X1 Pharmacy Prescriber
utilised.
Setting:
• X1 Tertiary Hospital
• Elective Surgery
Preadmissions clinic (PAC)
at Princess Alexandria
Hospital, Brisbane,
Australia.
Primary clinical outcome:
Frequency of omission &
prescribing errors when
compared against patient’s
medical history. The clinical
significance was also
analysed.
Secondary clinical outcome:
Appropriateness of VTE
prophylaxis prescribing.
Clinical outcomes:
Significantly less
unintended omissions of
medications by group A
compared to group B.
Significantly less
prescribing errors
involving selection of drug,
dose or frequency by group
A compared to group B.
VTE prophylaxis on
admission to the ward
approx. 93% group A &
90% group B, revealing no
significant difference.
No difference in
appropriateness of VTE
prophylaxis on admission
between the two groups.
NMP Qualification:
Independent Pharmacist
Prescribing Course
accredited by the General
Pharmaceutical Council,
UK.
NMP- Pharmacists
Independent Prescribing.
An amendment was
facilitated to the
Queensland Health
(Drugs and Poisons)
Regulation 1996 to enable
the qualified pharmacists
to prescribe in
Queensland, Australia.
Power calculations based
on pilot data used to
calculate sample size.
(Continued)
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No comparable secondary outcome measures were used across the three trials. Bruhn et al
(2013) assessed pain using the ‘Chronic Pain Grade’ measure and anxiety and depression with
the ‘HADS’ (Hospital Anxiety and Depression Scale). The other trials focused on the uses of
the medicines prescribed, with one trial examining the appropriateness of VTE prophylaxis
prescribing [27] and the other examining the number of medications chartered at an incorrect
dose or frequency, and the number of missed doses of specific medications post operatively
[28].
Outcomes: Cost effectiveness
The PIPPC trial evaluated the costs associated with: intervention, pain related hospitalisation,
primary care visits for chronic pain, primary care chronic pain related telephone contacts, and
prescribed and non-prescribed OTC pain related medicines [26]. Quality-adjusted life years
(QALYs) were calculated [26]. The QALYs in the PIPPC trial were generated from the associ-
ated costs and analysis of clinical outcomes from the SF-6D (patient reported outcome mea-
sure). As this trial was a pilot, the expected value of sample information was calculated to
assess whether a definitive trial would be worthwhile.
Risk of bias
100% inter-reviewer agreement was achieved regarding risk of bias assessment, with no media-
tion required from the third reviewer. Table 2 provides a summary of the overall risk of bias
assessed using the Cochrane Risk of Bias Tool for each included trial. Of the three included tri-
als, one was high risk of bias [27], one unclear [28], and one low risk of bias [26, 29]. Marotti
et al (2011) was assessed as unclear risk of bias, as the reviewers were unable to view the regis-
tered trial protocol, therefore bias owing to selective outcome reporting remained unclear.
Table 1. (Continued)
Trial Design Participants & Indication Intervention & Setting Outcome Measures Between Group Results Additional Information
Marotti
et al, 2011
[28]
RTC:
Three Groups:
A. Pharmacist medication
history plus
supplementary
prescribing.
B. Pharmacist medication
history taking, prescribing
through usual process.
C. TAU.
Blinded computer-
generated randomisation.
Conducted between Nov
2008- March 2009
All adults (no definition)
elective surgery patients
excluding orthopaedics.
Patients excluded if: no
regular medications,
unable to provide consent,
medications charted at a
pre-op clinic appointment,
day case.
Baseline:
A. n = 118, median (IQR)
age 64 (47–75), 51% male
B. n = 119, median (IQR)
age 62 (52–71), 55% male
C. n = 118, median (IQR)
age 65 (54–75), 49% male
Intervention:
Groups A&B- pharmacists
interviewed patients at the
time of admission on day of
surgery & documented
regular medication list.
Group A- the pharmacist
prescribed the regular
medications on the
medication chart via
supplementary prescribing.
Group C- patients had no
interaction with the
pharmacist prior to surgery.
Medications were charted
immediately post-surgery
by the medical officer in the
normal time frame.
Setting:
• X1 Tertiary Hospital. All
surgical units, John Hunter
Hospital, Newcastle, NSW,
Australia.
Primary clinical outcome:
The number of medication
doses missed
inappropriately during the
inpatient stay.
Secondary clinical outcome:
Number of medications
charted at incorrect dose or
frequency.
Number of missed
medication doses post
operatively of significant
medications e.g. beta
blockers, 3-hydroxy-
3-methyl-glutaryl-CoA
reductase inhibitors,
antiplatelets, anticoagulants.
Clinical Outcomes:
Significantly reduce
number of missed doses
per patient during hospital
stay for group A (p = 0.02)
but not group B compared
to group C.
Significantly less
medications charted at an
incorrect dose for Groups
A (p<0.001) &B
(p = 0.004) compared to
group C, with group A
having less errors that
group B.
Significantly less numbers
of medications charted at
an incorrect frequency by
groups A&B compared to
group C (p<0.001).
Non-medical prescribing
qualification/ credential/
accreditation not
disclosed.
NMP- Pharmacists
supplementary
prescribing.
No power calculations
used to calculate sample
size.
IP- Independent Prescribing, SP- Supplementary Prescribing, CPG- Chronic pain grade (CPG), HADS- Hospital Anxiety & Depression Score, PSSRU- Personal Social
Services Research Unit, QALYs- Quality-adjusted life years, TAU- Treatment as usual, Venous thromboembolism- VTE, PAC- Pre-admission clinic, ROM- Resident
Medical Officer
https://doi.org/10.1371/journal.pone.0193286.t001
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Hale et al (2013) was assessed as high risk of bias with the domain ‘blinding of participants’
rated at high risk, whilst all other domains were rated low risk. It was agreed that the weight of
this domain to overall risk of bias within the RCT was substantial, as the resident medical offi-
cers involved in the trials were aware of the pharmacist prescribing as part of a formal study.
Losses to follow-up were reported in all included trials [27, 28]. Across all trials, losses were less
than 20% and therefore considered acceptable [30]. The overall risk of bias across trials was
evaluated as unclear as 75% of the included studies were rated as low or unclear risk of bias [24].
Summary measures and synthesis of results
Clinical Effectiveness Outcomes. SF-12v2: for functional health and wellbeing from the
patient’s perspective, the PIPPC trial[26, 29] at low risk of bias found no significant difference
(p = 0.75) between groups.
Chronic Pain Grade (CPG): for overall chronic pain severity (pain intensity and pain-related
disability), the trial by Bruhn et al (2013) at low risk of bias found significant improvement on the
pain intensity subscale (p = 0.02) for the pharmacist experimental prescribing groups when com-
pared to treatment as usual. This improvement was not found for the disability subscale (p = 0.55).
Hospital Anxiety and Depression Scale (HADS): for depression, anxiety and emotional
distress, the trial by Bruhn et al (2013) at low risk of bias found that both the experimental
groups involving prescribing pharmacists were seen to improve significantly more compared
to the treatment as usual group (Group A p = 0.022, Group B p = 0.045).
The frequency of omission and prescribing errors: when compared against a patient’s medi-
cal history, the trial by Hale et al (2013) which was at high risk of bias found significantly less
unintended omissions of medications when prescribed by the pharmacist (p<0.001). There
were significantly fewer prescribing errors concerning selection of drug, dose or frequency in
the non-medical prescribing group (p<0.001), and significantly less medication orders from
the NMP group with at least one constituent of the prescription missing, incorrect or impre-
cise compared to that of the control group (p<0.001).
Prescription of VTE prophylaxis: the trial by Hale et al (2013) at high risk of bias found no
significant difference between the NMP group and the control group (p = 0.29) for the appro-
priateness of prescription of VTE prophylaxis.
Table 2. Summary assessment of the overall risk of bias for each study.
Study Domain of risk of bias Summary within
study
Comments on high-risk components
1 2 3 4 5a 5b 6
PIPPC Trial [26,
29]
L L L L L L L Low (7)
Hale et al, 2013
[27]
L L H L L L L Low (6)
High (1)
One high risk domain: 3
“RMO’s in clinic during the study were aware of the intervention pharmacist’s role, which may have
led to an increased number and quality of medication charts prescribed in the control arm.”
Marotti et al,
2011[28]
L L L L U U L Low (5)
Unclear (2)
Overall risk of bias across studies Unclear risk of bias
Domain of risk of bias: 1, sequence generation; 2, allocation concealment; 3, blinding of participants; 4, incomplete outcome data; 5a, short-term selective outcome
reporting; 5b, long-term selective outcome reporting 6, other sources of bias.
Levels of risk of bias: L, low risk of bias; U, unclear risk of bias; H, high risk of bias
Summary within study: Low, low risk of bias for all key risk criteria; Unclear, unclear risk of bias for all key risk criteria; High, high risk of bias for all key risk criteria.
RMO- Resident Medical Officer
https://doi.org/10.1371/journal.pone.0193286.t002
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The number of medication doses missed inappropriately during an inpatient stay: the
trial by Marotti et al (2011) that had an unclear risk of bias, found a significant difference (p =
0.002) between the pharmacist supplementary prescribing group compared to the pharmacist
drug history taking group and the control group for the number of medication doses inappro-
priately missed during an inpatient stay. The number of drugs charted at the wrong dose and/
or frequency was significantly reduced in the pharmacy history taking group and the pharma-
cist-prescribing group (p<0.001), compared to that of the control group. The pharmacist-pre-
scribing group were also seen to have fewer dose errors compared to the pharmacy drug
history taking group (p = 0.004).
Cost Effectiveness Outcomes. Associated Costs: the PIPPC trial [26] which had a low
risk of bias, found that both pharmacist prescriber-led intervention groups were less costly
than TAU based on raw unadjusted mean total costs. Adjustment for variances in baseline
costs and controlling for baseline participant characteristics resulted in a positive incremental
mean cost difference for both the experimental groups compared to the TAU group. Following
adjustments, both pharmacist prescribing and review groups were significantly (regression
coefficient p = 0.00) more expensive than usual care secondary to baseline costs.
Quality-Adjusted Life Years (QALYs): the PIPPC trial [26] at low risk of bias found for
unadjusted data, that both experimental groups generated increased QALYs compared to
TAU. Following adjustment for baseline costs, pharmacist-led groups were largely unchanged
relative to the TAU (‘pharmacist prescribing’ group, 0.0069 QALYs, <-0.0091 to 0.0229>,
‘pharmacist medication review’ group, 0.0097QALYs, <-0.0054 to 0.0248>), although the
adjusted difference in cost was reduced in the prescribing group (£21, from -£124 to £167) and
increased in the review group (£75, from -£72 to £221) relative to the TAU group.
Additional analyses
Meta-analysis was not justified owing to insufficient homogeneity of the outcome measures
used across the trials. Although the interventions used across the trials were similar, the low
number of trials included compounds the heterogeneity of the outcome measures.
Discussion
Summary of evidence
Owing to the low number of included trials and overall unclear risk of bias, recommendations
about NMP in the context of its potential clinical and cost-effectiveness are limited. Adequate
patient safety and clinical outcomes are key elements in clinical effectiveness required for the
valid and ethical use of any clinical intervention. Evidence with an overall unclear risk of bias
across the trials investigating the safe practice of NMP on tertiary care surgical wards, indicates
that NMP may lead to a significant reduction in omissions and prescribing errors, with the
medications prescribed by medical and non-medical prescribers being equally appropriate[27,
28]. Further, the PIPPC pilot trial low risk of bias evidence[29], suggests that NMP is practical,
acceptable and leads to improvement in pain outcomes in primary care. However, it is unclear
from the PIPPC trial data whether the participants’ improved pain outcomes were due to the
changes in medication prescribed by the pharmacists and/or participants’ education regarding
optimal timing for administration of the medications. The heterogeneity of the included trials
did not allow for meta-analysis. This evidence, when combined with the findings from the pre-
vious Cochrane review [31], might indicate that non-medical prescribers can independently
optimise medication management for chronic pain as effectively as medical prescribers, and
therefore have the potential to effectively support over-stretched medical practitioners working
in pain management in primary care.
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Embedding a new clinical tool or process into practice often requires explicit economic
benefit before it is adopted by a health community [3, 11]. For this reason, it was surprising
that only one pilot RCT evaluating the cost-effectiveness of NMP exists[26], even though NMP
is now widely practised internationally by a range of health professions. It is important that the
results of this trial are interpreted in the context of it being a pilot trial, with the aim to estimate
optimal sample size for a definitive trial, not to determine effectiveness. The trial’s results [26],
evaluated as having low risk of bias, suggest at first glance that pharmacist prescribing may be
more costly than traditional treatment once baseline costs are accounted for (e.g. education
costs required for pharmacist prescribers to become qualified, endorsed and registered as non-
medical prescribers). However, these baseline costs relate directly to the development of new
services that use NMP, where non-medical prescribers do not currently exist and full support
for new non-medical prescribers is required. This may be short sighted, reflecting only initial
set-up costs, rather than future long-term patient care. As the development, implementation
and utilisation of NMP varies across professions internationally, future economic assessment
should ensure that both initial and ongoing costs are analysed, establishing economic bench-
marks for future comparisons. The SF-6D outcome measure was used to calculate a QALY
effect[26], with results indicating that the use of non-medical prescribers generated increased
QALYs. However, incomplete data (one third of questionnaires incomplete), possibly owing
to participant understanding and the complexity of the measure [26] may have had significant
influence on the outcomes and should be considered further prior to the design of an ade-
quately powered definitive trial.
Comparison of the results from this review with the wider literature is difficult, as no RCTs
in addition to those included in the present review have been undertaken, and there are no
previous systematic reviews. The majority of research has concentrated on reporting the expe-
riences of stakeholders and has not used validated outcome measures to investigate cause and
effect relationships related to the uses of NMP[26]. The potential benefits of NMP in terms of
clinical and cost-effectiveness are illustrated by the included trials, however the deficit of low
risk of bias RCTs across professions, specialties and settings, highlights the need for adequately
powered low risk of bias RCTs to inform both clinical and cost-effectiveness across important
outcome measures. In order to enhance the quality and comparability of future RCTs, the
development of a minimum data-set of important outcome measures for the assessment of
NMP would be beneficial, providing healthcare managers, clinical care quality and safety agen-
cies as well as the general public with the require evidence needed to evaluate the overall value
of NMP.
Strengths and limitations of the review
This is the first systematic review to synthesise the existing evidence using rigorous methods to
provide clarity of the level and quality of existing evidence. Evaluation of the evidence using
GRADE (the Grading of Recommendations Assessment, Development and Evaluation system)
assessment revealed moderate quality evidence for both the clinical and cost effectiveness of
NMP (Table 3)[32]. However, the limited number of trials available for inclusion and overall
unclear risk of bias of the included trials limits the external validity of the review. Each trial
used different outcome measures limiting scope for meta-analysis, due to limited homogene-
ity. Only NMP by pharmacists was investigated limiting generalisability across all professions.
Limitations in the diversity of the included nations, specialties, methods of NMP (independent
versus supplementary) and the nature of the use of NMP were evident between the included
studies, resulting in high heterogeneity, limiting their comparability and ability to make
generalisations.
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Conclusions
This systematic review has identified limited evidence with moderate quality and unclear risk
of bias evaluating the clinical effectiveness of NMP across all professions and clinical settings.
Three trials have shown significant results indicating that NMP is safe and can provide effec-
tive clinical outcomes for patients. The benefit to the health economy remains unclear, with
the cost-effectiveness of NMP assessed by a single pilot RCT that, although at low risk of bias,
by its nature was not powered to evaluate cost-effectiveness. Adequately powered low risk of
bias RCTs, evaluating safety, quality, appropriateness of care and economic benefit across a
range of clinical professions, specialties and settings is urgently required. Evidence from future
RCTs can then be used to inform politicians, policy makers, clinicians and healthcare manag-
ers when considering the utilisation of NMP in the planning and provision of future quality
and effective healthcare services[3, 4]. The development of a minimum data-set of outcome
measures is required to ensure homogeneity/ comparability of data when analysing and assess-
ing non-medical prescribing within and across individual clinical fields, professions, and
across international healthcare boundaries.
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